Last updated: February 19, 2026
Vecuronium bromide is a non-depolarizing neuromuscular blocking agent used in anesthesia to facilitate intubation and muscle relaxation during surgery. The drug is manufactured by multiple pharmaceutical companies worldwide, with some supplying proprietary formulations and others offering generic versions.
Major Suppliers and Manufacturers
| Company Name |
Location |
Product Name |
Approval Status |
Manufacturing Capacity |
Notes |
| Fresenius Kabi |
Germany |
Vecuronium Bromide Injection |
EMA, FDA, other regulatory approvals |
Large-scale |
Offers both branded and generic versions |
| Teva Pharmaceutical Industries |
Israel |
Vecuronium Bromide |
FDA, EMA approved |
Extensive global distribution |
Known for generic injectables |
| Hikma Pharmaceuticals |
UK |
Vecuronium Bromide |
Multiple regulatory bodies |
Significant |
Focus on generics in Middle East and Europe |
| GlaxoSmithKline (GSK) |
UK |
Vecuronium Bromide |
Signal presence |
Moderate |
Discontinued some formulations but active in markets |
| Sun Pharmaceutical Industries |
India |
Vecuronium Bromide |
Regulatory approvals in India and abroad |
Large capacity |
Active as both producer and exporter |
| Jiangsu Hengrui Medicine |
China |
Vecuronium Bromide |
Approved in China |
Growing |
Increasing presence in Asian markets |
| West-Ward Pharmaceuticals (part of Mylan) |
US |
Vecuronium Bromide |
FDA approved |
Large capacity |
Focused on US and emerging markets |
| Hikma Pharmaceuticals |
UK |
Vecuronium Bromide |
EC and other approvals |
Significant |
Emphasizes cost-effective generics |
Key Considerations
- Regulatory Approvals: The list indicates companies with products approved by major agencies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Approval status affects market entry and distribution scope.
- Manufacturing Capacity: Leaders in production capacity such as Fresenius Kabi, Teva, and Sun Pharma can supply large volumes, essential for hospitals and bulk distribution.
- Geographic Focus: Suppliers such as Jiangsu Hengrui focus on Asian markets, while West-Ward and Hikma serve North American and Middle Eastern regions.
- Product Forms: Suppliers typically offer injectable formulations, the most common form for institutional use in anesthesia.
Notes on Market Dynamics
- Generics dominate the global supply, with patents expiring over the past decade.
- Asian and Middle Eastern companies increasingly fill manufacturing roles due to cost advantages.
- Quality control and regulatory compliance remain critical for supplier selection, especially for injectable anesthetics.
Regulatory Landscape
- Approval processes vary by country; suppliers must obtain and maintain approvals from local health authorities.
- The US FDA's approval process involves pre-market inspections, stability testing, and bioequivalence assessments.
- The European market requires EMA approval, with strict Good Manufacturing Practice (GMP) standards.
Key Takeaways
- Multiple manufacturers, including Fresenius Kabi, Teva, Hikma, Sun Pharma, and Jiangsu Hengrui, supply Vecuronium bromide globally.
- Chinese and Indian producers have increased their market share due to lower manufacturing costs.
- Regulatory approvals from agencies such as the FDA and EMA are critical for market access.
- Capacity and geographic reach vary, affecting availability in different regions.
- The marketplace is primarily supplied through generic manufacturers.
FAQs
1. Which companies supply Vecuronium bromide globally?
Main suppliers include Fresenius Kabi, Teva, Hikma, Sun Pharma, and Jiangsu Hengrui, with approvals in various regions.
2. What factors influence the choice of a Vecuronium bromide supplier?
Regulatory approval, manufacturing capacity, product quality, geographic coverage, and cost.
3. Are generic Vecuronium bromide products as effective as branded ones?
Yes, provided they meet regulatory standards for bioequivalence and quality.
4. How does regulatory approval impact supplier selection?
Approval ensures compliance with safety standards, allowing distribution and use in specific regions.
5. What trends are influencing Vecuronium bromide supply?
Growing markets in Asia, increased generic manufacturing, and regulatory harmonization.
References
[1] U.S. Food and Drug Administration. (2023). Approved Drug Products List. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (2023). List of medicines authorised by the EMA. Retrieved from https://www.ema.europa.eu/en
[3] Pharmaceutical Market Reports. (2022). Global neuromuscular blocking agents market.
